Abstract
Neutropenia is a significant dose-limiting toxicity of cancer chemotherapy, especially in dose-intensified regimens. It is widely treated by injections of Granulocyte Colony-Stimulating Factor (G-CSF). However, optimal schedules of G-CSF administration are still not determined. In order to aid in identifying more efficacious and less neutropenic treatment protocols, we studied a detailed physiologically-based computer model of granulopoiesis, as affected by different treatment schedules of doxorubicin and/or Granulocyte Colony-Stimulating Factor (G-CSF). We validated the model as evident from accurate prediction of clinical data on human granulopoiesis in healthy individuals and in doxorubicin-treated cancer patients, with or without G-CSF support. Based on our model, we suggest new G-CSF administration regimens. These regimens include reduced G-CSF doses, optimally timed post-chemotherapy. Application of these regimens can lead to minimization of G-CSF side effects, as well as more cost-effective and less myelotoxic protocols. Currently clinical trials are being designed in order to test these new treatment regimens.
| Original language | English |
|---|---|
| Pages (from-to) | 70-80 |
| Number of pages | 11 |
| Journal | Mathematical Modelling of Natural Phenomena |
| Volume | 1 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 2006 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- chemotherapy
- granulopoiesis
- mathematical modeling
- treatment optimization
ASJC Scopus subject areas
- Modeling and Simulation
- Applied Mathematics
Fingerprint
Dive into the research topics of 'Improving cancer therapy by doxorubicin and granulocyte colony-stimulating factor: Insights from a computerized model of human granulopoiesis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver